Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
DOXORUBICIN HYDROCHLORIDE
Hospira UK Limited
L01DB01
DOXORUBICIN HYDROCHLORIDE
50 Milligram
Pdr for Soln for Injection
Product subject to prescription which may not be renewed (A)
Anthracyclines and related substances
Authorised
1991-06-25
PACKAGE LEAFLET: INFORMATION FOR THE USER DOXORUBICIN HYDROCHLORIDE 50 MG POWDER FOR SOLUTION FOR INJECTION READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. If you get any side effects, tell your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Doxorubicin Hydrochloride Powder for Solution for Injection is and what it is used for 2. What you need to know before you use Doxorubicin Hydrochloride Powder for Solution for Injection 3. How to use Doxorubicin Hydrochloride Powder for Solution for Injection 4. Possible side effects 5. How to store Doxorubicin Hydrochloride Powder for Solution for Injection 6. Contents of the pack and other information 1. WHAT DOXORUBICIN HYDROCHLORIDE POWDER FOR SOLUTION FOR INJECTION IS AND WHAT IT IS USED FOR Doxorubicin Hydrochloride Powder for Solution for Injection contains the active substance doxorubicin. Doxorubicin Hydrochloride Powder for Solution for Injection is an anti-cancer medicine. Treatment with an anti-cancer medicine is sometimes called cancer chemotherapy. Doxorubicin is used in the treatment of certain types of cancer, for example, cancers of the blood (leukaemia), breast, soft tissue, bone, lung and bladder. It is also used in the treatment of some cancers in children. Doxorubicin is often given with other anti-cancer medicines. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE DOXORUBICIN HYDROCHLORIDE POWDER FOR SOLUTION FOR INJECTION YOU SHOULD NOT BE GIVEN DOXORUBICIN HYDROCHLORIDE POWDER FOR SOLUTION FOR INJECTION IF Olvassa el a teljes dokumentumot
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Doxorubicin Hydrochloride 50 mg Powder for Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Doxorubicin hydrochloride 50.0 mg per vial. Excipient: Lactose monohydrate 263.1 mg When reconsituted as recommended in section 6.6 each ml contains 2 mg doxorubicin hydrochloride. For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder for solution for injection. Orange-red, sterile, freeze-dried powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Doxorubicin has been used successfully in the treatment of neoplastic conditions such as acute leukaemia, soft tissue and osteogenic sarcomas, breast carcinoma, lymphomas, bronchogenic (lung) carcinoma. It has also been used in the treatment of paediatric malignancy. Doxorubicin is frequently used in combination chemotherapy regimen involving other cytotoxic drugs. Doxorubicin can be used in the treatment of non-metastatic transitional cell carcinoma, carcinoma in situ and papillary tumours of the bladder, by intravesical administration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION INTRAVENOUS ADMINISTRATION When used as a single agent, the recommended dosage schedule is 60- 75 mg/m² body surface area, as a single intravenous injection administered at 21 day intervals. If it is used in combination with other antitumour agents having overlapping toxicity, the dosage for doxorubicin may need to be reduced to 30-40 mg/m² every three weeks. If using body weight to calculate the dose, then dosages of 1.2 - 2.4 mg/kg as a single dose every three weeks are recommended. It has been shown that giving doxorubicin as a single dose every three weeks greatly reduces the distressing toxic effect, mucositis. However, there are some regimens which divide t Olvassa el a teljes dokumentumot